Podcasts

E-Books

Videos

Articles

Clinical

Tony Hagen is senior managing editor for The Center for Biosimilars

Lotus and CKD Pharmaceutical intend to be among the first to bring a darbepoetin alpha biosimilar to Southeast Asia.

Lotus Inks Deal With CKD to Distribute Darbepoetin Alpha Biosimilar

Isha Bangia, PharmD, MBA, is a manager of US market access at Certara Evidence & Access. She received her PharmD from Rutgers University and an MBA from Johns Hopkins University. Her current responsibilities include optimizing product value stories and working with customers to improve access across the US healthcare system. Her experience includes practicing pharmacy, payer market research, and pharma strategy and analytics. Her work has covered many therapeutic areas, including biosimilars, oncology, diabetes, vaccines, and rare diseases.

Amgen's Onpro autoinjector device for pegfilgrastim is a stunning example of how product differentiation via drug delivery devices can protect market share in the biologics market.

Contributor: Drug Delivery Devices Help Originator Companies Retain Market Share

Singapore-based PrestigePharma presents fresh equivalency data supporting its case for regulatory approval of HD201.

PrestigePharma Reports Positive PK Data for Bevacizumab Candidate

The American College of Physicians (ACP) said many reforms are needed to install appropriate checks and balances in the biologic drugs marketplace. 

ACP Calls for Biologics Marketplace Reforms

Courts have allowed biosimilar developers "safe harbor" against infringement suits, but there are limits, attorneys from Goodwin Proctor explain.

Goodwin Attorneys Discuss Hospira-Amgen Infringement Case

This summer, The Center for Biosimilars® interviewed several experts for their opinions on the current need for biosimilars and how companies are working to overcome barriers to uptake. Here are some highlights.
 

Expert Opinion Roundup: Overcoming Barriers to Biosimilar Uptake

Bio-Thera said it has begun testing the safety its ustekinumab biosimilar in healthy volunteers.

Bio-Thera Begins Phase 1 Trial for Ustekinumab Biosimilar

Some European markets are more formidable than others with regard to complexity and getting biosimilars established, but there are good places to start, Jonathan Sweeting, head of Europe for Samsung Bioepis, explains.

Samsung Bioepis Exec Discusses European On-Ramp for Aybintio 

It’s same old, same old when it comes to pharmacy benefit manager (PBM) contracts despite much touted reforms, authors of a review contend.
 

Report: PBM "Reforms" Leave Biosimilars Out in the Cold

The Australia-based biosimilar company hopes to compete with blockbuster programmed death-1 (PD-1) inhibitor franchises owned by Merck and Bristol Myers Squibb.

Oncology